Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 7:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–43 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Ranitidine Clear all
Withdrawn Phase 4 Interventional

The Study of Eustachian Tube Dysfunction and Laryngopharyngeal Reflux

NCT02123498
View directory record Official record
Conditions
Eustachian Tube Dysfunction, Laryngopharyngeal Reflux
Interventions
Omeprazole, Ranitidine, Pantoprazole, 24-Hour Diagnostic pH-Probe Test, Laryngoscopy
Drug · Procedure
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Loma Linda, California • Redlands, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2016 · Synced Sep 21, 2026, 7:59 PM EDT
Completed Phase 3 Interventional Results available

Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)

NCT00839306
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Rabeprazole ER, Ranitidine
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
4
States / cities
Moline, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Sep 21, 2026, 7:59 PM EDT
Not listed No phase listed Observational

Management of Esophagitis Following Repair of Esophageal Atresia

NCT03619408
View directory record Official record
Conditions
Esophageal Atresia, Esophagitis
Interventions
Antacids
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
30 Days to 17 Years
Enrollment
50 participants
Timeline
2019 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced Sep 21, 2026, 7:59 PM EDT
Terminated Phase 2 Interventional Results available

Corticosteroids With Placebo Versus Corticosteroids With Propranolol Treatment of Infantile Hemangiomas (IH)

NCT01074437
View directory record Official record
Conditions
Hemangioma
Interventions
Prednisolone (Corticosteroid), Propranolol, Placebo
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
Up to 9 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Sep 21, 2026, 7:59 PM EDT
Completed Not applicable Interventional Results available

Extending Acute Stroke Trials to the Aerial Inter-hospital Transfer Setting

NCT00585351
View directory record Official record
Conditions
Stroke
Interventions
Ranitidine, Placebo, Advanced notification, No advanced notification
Drug · Other
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Sep 21, 2026, 7:59 PM EDT
Terminated Phase 4 Interventional

Lansoprazole Preventing Gastroduodenal Stress Ulcerations

NCT00220909
View directory record Official record
Conditions
Patients Undergoing Elective Coronary Artery Bypass Graft
Interventions
Lansoprazole
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 10, 2008 · Synced Sep 21, 2026, 7:59 PM EDT
Withdrawn Not applicable Interventional

In Infants With Laryngomalacia, Does Acid-Blocking Medication Improve Respiratory Symptoms?

NCT02700087
View directory record Official record
Conditions
Laryngomalacia, Acid Reflux, Stridor
Interventions
ranitidine or famotidine, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
Up to 4 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Sep 21, 2026, 7:59 PM EDT
Completed Phase 1 Interventional Results available

A Study of LY2090314 in Patients With Advanced or Metastatic Cancer

NCT01287520
View directory record Official record
Conditions
Advanced Cancer
Interventions
LY2090314, pemetrexed, Carboplatin, ranitidine
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
25 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Tampa, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 24, 2019 · Synced Sep 21, 2026, 7:59 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

: Vascular Function in Health and Disease

NCT02966665
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure, Hypertension
Interventions
Maximum Exercise Tests, BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine, BQ-123, MitoQ, BH4
Other · Drug
Lead sponsor
Russell Richardson
Other
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Sep 21, 2026, 7:59 PM EDT
Completed Phase 2 Interventional Results available

Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer

NCT01248962
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
carboplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Sep 21, 2026, 7:59 PM EDT
Completed Phase 1 Interventional

Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer

NCT01411410
View directory record Official record
Conditions
Neoplasms
Interventions
Paclitaxel, Copanlisib (BAY80-6946)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
St Louis, Missouri • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2017 · Synced Sep 21, 2026, 7:59 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma

NCT02541643
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab
Drug
Lead sponsor
Sundar Jagannath
Other
Eligibility
18 Years and older
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2015 · Synced Sep 21, 2026, 7:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study in Healthy Subjects

NCT00924911
View directory record Official record
Conditions
Infections, Bacterial
Interventions
GSK1322322
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2017 · Synced Sep 21, 2026, 7:59 PM EDT
Completed Phase 1 Interventional

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

NCT04681105
View directory record Official record
Conditions
Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hairy Cell Leukemia, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent T Acute Lymphoblastic Leukemia, Refractory Acute Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Hairy Cell Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory T Acute Lymphoblastic Leukemia, Systemic Mastocytosis
Interventions
Acetaminophen, Dexamethasone, Diphenhydramine, Flotetuzumab, Ibuprofen, Ranitidine
Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
12 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 21, 2026, 7:59 PM EDT
Completed Phase 1 Interventional

Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma

NCT01042704
View directory record Official record
Conditions
Myeloma
Interventions
Bendamustine, Lenalidomide, Dexamethasone, Aspirin, Prophylaxis, Antibiotic, Biweekly Follow Up, Cyclical Follow Up, Restaging, Post-Treatment Follow Up
Drug · Other
Lead sponsor
Robert Redner, MD
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
22
States / cities
Detroit, Michigan • Steubenville, Ohio • Beaver, Pennsylvania + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2017 · Synced Sep 21, 2026, 7:59 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation

NCT04294459
View directory record Official record
Conditions
Immune System Disorder
Interventions
Isatuximab SAR650984, Acetaminophen (paracetamol) or equivalent, Ranitidine or equivalent, Diphenhydramine or equivalent, Methylprednisolone or equivalent, Montelukast or equivalent
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
San Francisco, California • Rochester, Minnesota • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 21, 2026, 7:59 PM EDT
Withdrawn Phase 4 Interventional

Total Antioxidant Effects of Esomeprazole in Dyspeptic Patients Receiving Non-steroidal Anti-inflammatory Drugs

NCT00443963
View directory record Official record
Conditions
Dyspepsia
Interventions
Esomeprazole Magnesium
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 23, 2020 · Synced Sep 21, 2026, 7:59 PM EDT
Completed Phase 1 Interventional

The Effect of Stomach Acid on Foscarnet

NCT00000964
View directory record Official record
Conditions
HIV Infections
Interventions
Ranitidine hydrochloride, Foscarnet sodium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 21, 2026, 7:59 PM EDT
Completed Phase 2 Interventional Results available

Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer

NCT00655850
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Paclitaxel, Gemcitabine, Avastin
Drug · Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 16, 2017 · Synced Sep 21, 2026, 7:59 PM EDT